Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29276158 | 1.00 | SCN4A (0.33) | SCN4AMAPTSMN1; SMN2L3MBTL1MAP3K14 | |
| SCHEMBL30994104 | 0.84 | MAPT (0.33) | MAPTSMN1; SMN2L3MBTL1PLAU | |
| SCHEMBL26440052 | 0.83 | SCN4A (0.32) | SCN4A | |
| SCHEMBL31405007 | 0.83 | SCN4A (0.32) | SCN4A | |
| SCHEMBL23883881 | 0.82 | KDM4E (0.33) | MAPTPLAU | |
| SCHEMBL30335376 | 0.82 | KDM4E (0.33) | MAPTPLAU | |
| SCHEMBL30994961 | 0.81 | PLAU (0.31) | PLAU | |
| SCHEMBL29276192 | 0.81 | PLAU (0.31) | PLAU | |
| SCHEMBL13494625 | 0.79 | MAP3K14 (0.44) | MAPTSMN1; SMN2L3MBTL1MAP3K14 | |
| SCHEMBL30994139 | 0.79 | PTPN1 (0.30) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656635-A1 | SUBSTITUTED BENZENE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| WO-2024157953-A1 | SUBSTITUTED BENZENE COMPOUND | 第一三共株式会社 | 2024-08-02 | — | — | WO | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | SCN4A 1461/4885MAPT 1512/4885SMN1; SMN2 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.